Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

This study has been completed.
Sponsor:
Information provided by:
Nordic Myeloma Study Group
ClinicalTrials.gov Identifier:
NCT00602511
First received: January 15, 2008
Last updated: February 8, 2011
Last verified: February 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2010
  Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)